NCT04280510|Recruiting
Pathogenic Study of Adult Immune Enteropathies
ENTEROPATH
Loading search results
ENTEROPATH
Sponsor study identifier
Secondary identifiers
REGISTRY · ID-RCB
observational
200
1 country
4
Study Start
February 27, 2020
Actual (reported)Primary Completion
February 27, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 27, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 27, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 20, 2020
Actual (reported)February 21, 2020
Actual (reported)February 27, 2020
Actual (reported)February 27, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 27, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Intestinal Lymphocytes count
Lymphocytes isolation
Baseline
DNA sequencing
Targeted Next Generation sequencing
Baseline
Patients with active coeliac disease
Patients with coeliac disease on gluten free diet
Patients with refractory coeliac disease of type I
Patients with refractory coeliac disease of type II
Patients with intestinal lymphoproliferations
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Patients planned to have blood specimens and possible upper and/or lower digestive endoscopy.
Hôpital Henri Mondor
Créteil, 94010, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270, France
Georgia MALAMUT, MD, PhD
APHP, Université de Paris (Université Paris Descartes)
First Submitted
January 20, 2020
First Posted
February 21, 2020
Study Start
February 27, 2020
Actual (reported)Primary Completion
February 27, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease
Patients with non coeliac immune-mediated enteropathy
Patients without neoplastic or inflammatory intestinal disease
Contact the study team to confirm eligibility.
Hôpital Saint Louis
Paris, 75010, France
Hôpital Cochin
Paris, 75014, France
Study Completion
February 27, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 27, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: